— Know what they know.
Not Investment Advice

ADIL NASDAQ

Adial Pharmaceuticals, Inc.
1W: +4.8% 1M: +10.8% 3M: +81.0% YTD: -52.3% 1Y: +495.6% 3Y: -59.1% 5Y: -95.4%
$2.95
+0.14 (+4.98%)
 
Weekly Expected Move ±7.2%
$2 $3 $3 $3 $3
NASDAQ · Healthcare · Biotechnology · Alpha Radar Buy · Power 64 · $2.8M mcap · 954946 float · 48.19% daily turnover · Short 34% of daily vol
Smart Money Score
Bullish 75
Insider+$0.1M
Congress
ETF Holdings
Key Statistics
Market Cap$2.8M
52W Range1.31-19
Volume62,988
Avg Volume460,172
Beta1.43
Dividend
Analyst Ratings
3 Buy 0 Hold 0 Sell
Consensus Buy
Company Info
CEOCary John Claiborne
Employees5
SectorHealthcare
IndustryBiotechnology
IPO Date2018-07-27
Websiteadial.com
1180 Seminole Trail
Glen Allen, VA 22901
US
434 422 9800
About Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.

Recent Insider Trades

NameTypeSharesPriceDate
Coastlands Capital L P-Purchase 1,233 $2.75 2026-07-16
Coastlands Capital L P-Purchase 2,000 $2.65 2026-07-14
Coastlands Capital L P-Purchase 1,700 $2.70 2026-07-10
Coastlands Capital L P-Purchase 10,053 $2.79 2026-07-09
Coastlands Capital L P-Purchase 25,000 $2.60 2026-06-29

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms